Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
CDMC 2018: Shifting gears in the management of diabetes and CVD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- Dr. Adie Viljoen, MD
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
- Prof. Richard Hobbs, MD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The GLP1 landscape - refining our understanding
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
- Prof John E Deanfield